ALK Positive Archives
Newer targeted therapy prolongs life for lung cancer patients
Aug. 13, 2020—Patients with ALK-positive non-small cell lung cancer treated with ensartinib fared better and lived longer than those who received crizotinib, according to results of a phase 3 study.
Advocacy group’s gift boosts lung cancer research efforts
Feb. 13, 2020—An advocacy group for patients with anaplastic lymphoma kinase positive lung cancer has awarded a $500,000 grant dedicated to overcoming treatment resistance to the cancer.
Lung cancer patients and advocates visit VUMC research labs
Jun. 14, 2018—A group of young lung cancer patients and their family members recently toured research laboratories at Vanderbilt University Medical Center and Vanderbilt-Ingram Cancer Center (VICC) to learn how investigators are working to find better therapies and possibly a cure for the disease.
